"The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced.
Adalimumab is the first and o"...
Ilevro Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Ilevro (nepafenac) ophthalmic suspension, 0.3% is an ophthalmic nonsteroidal anti-inflammatory drug (ophthalmic NSAID) indicated for the treatment of pain and inflammation associated with cataract surgery. Common side effects of Ilevro include the sensation that a foreign body is in the eye, increased intraocular pressure, a sticky sensation in the eye, eye or eyelid swelling, dry eye, crusting of the eyelids, eye discomfort or pain, itchy eyes, sensitivity to light, tearing.
Ilevro is administered as drops into the affected eye(s). Ilevro should not be administered while wearing contact lenses. Additionally, if more than one topical ophthalmic medication is being used, the medicines must be administered at least five minutes apart. Ilevro should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The use of Ilevro during late pregnancy should be avoided. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ilevro is administered to a nursing woman.
Our Ilevro (nepafenac) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Ilevro FDA Prescribing Information: Side Effects
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Serious And Otherwise Important Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of labeling.
- Increased Bleeding Time (WARNINGS AND PRECAUTIONS)
- Delayed Healing (WARNINGS AND PRECAUTIONS)
- Corneal Effects (WARNINGS AND PRECAUTIONS)
Ocular Adverse Reactions
The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. These reactions occurred in approximately 5 to 10% of patients.
Other ocular adverse reactions occurring at an incidence of approximately 1 to 5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing and vitreous detachment. Some of these reactions may be the consequence of the cataract surgical procedure.
Non-Ocular Adverse Reactions
Read the entire FDA prescribing information for Ilevro (Nepafenac Ophthalmic Suspension)
Additional Ilevro Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.